

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A pharmaceutical preparation of microcapsules of lactic-co-glycolic copolymer which incorporates a peptide ~~of pharmaceutical interest~~ neither sensible to nor degradable by organic solvents, characterised in that ~~the polymer that forms the said~~ microcapsules incorporates ~~a citric acid ester as an additive and the peptide is not present on the surface of the microcapsule~~ provide a substantially linear release profile of said peptide over time.

2. (Currently amended) A pharmaceutical preparation of microcapsules according to claim 1 characterised in that said microcapsules incorporate ~~the~~ a citric acid ester is selected from triethyl citrate, tributyl citrate and acetyl tributyl citrate.

3. (Original) A pharmaceutical preparation of microcapsules according to claim 2 characterised in that the citric acid ester is triethyl citrate.

4. (Original) A preparation according to claim 3 characterised in that the amount of triethyl citrate contained in the preparation varies between 0.1% and 60% by weight of the copolymer.

5. (Currently amended) A pharmaceutical preparation according to claim 1 characterised in that the percentage ratio between the lactate and the glycolate units in the lactic-co-glycolic copolymer varies between 100% ~~and~~ of lactate and 90% of glycolate, both inclusive.

6. (Previously presented) A pharmaceutical preparation according to claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of LHRH.

7. (Currently amended) A pharmaceutical preparation according to claim 6 characterised in that the analog of LHRH is selected from tryptoreline, leuprolide, gosereline, busereline ~~[[or]]~~ and cetrotorelix.

8. (Previously presented) A pharmaceutical preparation according to claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is somatostatine or an analogue thereof.

9. (Original) A pharmaceutical preparation according to claim 8 characterised in that the analogue of somatostatine is octreotide.

10. (Previously presented) A pharmaceutical preparation according to claim 1 characterised in that the encapsulated peptide of pharmaceutical interest is an analogue of human calcitonine.

11. (Original) A pharmaceutical preparation according to claim 10 characterised in that the analogue of human calcitonine is salmon calcitonine or carbocalcitonine.